ASCO 2021 | Activity of EGFR TKIs in patients with NSCLC with uncommon EGFR mutations

Sanjay Popat, BSc, MBBS, FRCP, PhD, The Royal Marsden NHS Foundation Trust, London, UK, discusses the findings of a real-world cohort study evaluating the activity of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in patients with non-small cell lung cancer (NSCLC) with uncommon EGFR mutations. In a real-world setting, EGFR tyrosine kinase inhibitors were the preferred treatment approach in patients with uncommon EGFR mutations. This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.